Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations / Tausch, E., Ljungström, V., Agathangelidis, A., Zapatka, M., Scarfò, L., Jebaraj, B.M.C., Yosifov, D.Y., Müller, A., Munugalavadla, V., Degenhardt, J.D., Ghia, P., Rosenquist, R., Stilgenbauer, S.. - In: BLOOD. - ISSN 1528-0020. - 139:22(2022), pp. 3340-3344. [10.1182/blood.2021014550]
Secondary resistance to idelalisib is characterized by upregulation of IGF1R rather than by MAPK/ERK pathway mutations
Scarfò, Lydia;Ghia, Paolo
;
2022-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
